A prospective randomised phase-II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  European Journal of Cancer

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ejca.2014.10.010PMID 25459392
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• VEGF and Id-1 in pancreatic adenocarcinoma: prognostic significance and impact on angiogenesis.

  2014cited by this paper
• Curcumin Inhibits Tumor Growth and Angiogenesis in an Orthotopic Mouse Model of Human Pancreatic Cancer

  2013cited by this paper
• Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.

  2013cited by this paper
• Sunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding study

  2013cited by this paper
• Targeting Mitochondrial STAT3 with the Novel Phospho-Valproic Acid (MDC-1112) Inhibits Pancreatic Cancer Growth in Mice

  2013cited by this paper
• Phase I study of axitinib (AG-013736) in combination with gemcitabine in patients with advanced pancreatic cancer

  2012cited by this paper
• The efficacy of a novel, dual PI3K/mTOR inhibitor NVP‐BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer

  2012cited by this paper
• Phase I trial of sunitinib and gemcitabine in patients with advanced solid tumors

  2012cited by this paper
• Annual Report to the Nation on the status of cancer, 1975‐2008, featuring cancers associated with excess weight and lack of sufficient physical activity

  2012cited by this paper
• A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer

  2012cited by this paper
• A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma

  2012cited by this paper
• FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

  2011cited by this paper
• BAYPAN study: A double-blind, phase III randomized trial of gemcitabine plus sorafenib versus gemcitabine plus placebo in patients with advanced pancreatic cancer.

  2011cited by this paper
• Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study.

  2011cited by this paper
• Current State of Surgical Management of Pancreatic Cancer

  2011cited by this paper
• Downregulation of STAT3 signaling induces apoptosis but also promotes anti-apoptotic gene expression in human pancreatic cancer cell lines

  2011cited by this paper
• Predictive biomarkers for the activity of mammalian target of rapamycin (mTOR) inhibitors

  2011cited by this paper
• Targeting STAT3 Signaling in Pancreatic Cancer Promotes Antiapoptotic Gene Expression

  2011cited by this paper
• A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603).

  2010cited by this paper
• Sunitinib malate for gastrointestinal stromal tumour in imatinib mesylate-resistant patients: recommendations and evidence.

  2010cited by this paper
• Curcumin Inhibits Constitutive STAT3 Phosphorylation in Human Pancreatic Cancer Cell lines and Downregulation of Survivin/BIRC5 Gene Expression

  2009cited by this paper
• Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study.

  2008cited by this paper
• PKC 412 small‐molecule tyrosine kinase inhibitor

  2007cited by this paper
• Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

  2007cited by this paper
• Clinical trials of VEGF receptor tyrosine kinase inhibitors in pancreatic cancer

  2007cited by this paper
• Molecular genetics of pancreatic intraepithelial neoplasia.

  2007cited by this paper
• Tyrosine kinase inhibitors and gemcitabine: new treatment options in pancreatic cancer?

  2006cited by this paper
• Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer.

  2006cited by this paper
• Vascular endothelial growth factor receptor‐1 promotes migration and invasion in pancreatic carcinoma cell lines

  2005cited by this paper
• Simultaneous inhibition of EGFR, VEGFR, and platelet-derived growth factor receptor signaling combined with gemcitabine produces therapy of human pancreatic carcinoma and prolongs survival in an orthotopic nude mouse model.

  2005cited by this paper
• The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-κB and c-Myc in pancreatic cancer cells

  2005cited by this paper
• The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-κB and c-Myc in pancreatic cancer cells

  2004cited by this paper
• Pancreatic cancer growth is inhibited by blockade of VEGF-RII.

  2003cited by this paper
• SOP 02: Evaluation and Selection of a Clinical Trial Proposal for CESAR

  2003cited by this paper
• Molecular targets and cancer therapeutics: discovery, biology and clinical applications.

  2001cited by this paper
• [New guidelines to evaluate the response to treatment in solid tumors].

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors

  2000cited by this paper
• Expression of two angiogenic factors, vascular endothelial growth factor and platelet-derived endothelial cell growth factor in human pancreatic cancer, and its relationship to angiogenesis.

  1998cited by this paper

• Targeted and immunotherapy strategies in pancreatic ductal adenocarcinoma: Recent developments and insights.

  2025cites this paper
• Maintenance Therapy for Pancreatic Cancer, a New Approach Based on the Synergy between the Novel Agent GP-2250 (Misetionamide) and Gemcitabine

  2024cites this paper
• Angiogenesis and Pancreatic Cancer: Novel Approaches to Overcome Treatment Resistance.

  2024cites this paper
• Chemotherapy and radiotherapy for advanced pancreatic cancer.

  2024cites this paper
• Therapeutic advances targeting tumor angiogenesis in pancreatic cancer: Current dilemmas and future directions.

  2023cites this paper
• Sample size optimization for clinical trials using graphical approaches for multiplicity adjustment

  2023influential citation
• Case report: A case study on the treatment using icaritin soft capsules in combination with lenvatinib achieving impressive PR and stage reduction in unresectable locally progressive pancreatic cancer and a literature review

  2023cites this paper
• Current and emerging anti-angiogenic therapies in gastrointestinal and hepatobiliary cancers

  2022cites this paper
• Targeted therapy

  2022cites this paper
• Obesity and cancer—extracellular matrix, angiogenesis, and adrenergic signaling as unusual suspects linking the two diseases

  2022cites this paper
• Clinical Strategies Targeting the Tumor Microenvironment of Pancreatic Ductal Adenocarcinoma

  2022cites this paper
• Circulating Tumor DNA Tracking In Patients With Pancreatic Cancer Using Next-Generation Sequencing

  2022cites this paper
• Pembrolizumab enhances the anti-pancreatic cancer activity of anlotinib.

  2022cites this paper
• G2M checkpoint pathway alone is associated with drug response and survival among cell proliferation-related pathways in pancreatic cancer.

  2021cites this paper
• Role of Stroma in Pancreatic Cancer

  2021cites this paper
• Two decades of research toward the treatment of locally advanced and metastatic pancreatic cancer: Remarkable effort and limited gain.

  2021cites this paper
• The Role of Exosomes in Pancreatic Cancer From Bench to Clinical Application: An Updated Review

  2021cites this paper
• Pancreatic Adenocarcinoma Therapeutics Targeting RTK and TGF Beta Receptor

  2021cites this paper
• A systematic study of novel drug delivery mechanisms and treatment strategies for pancreatic cancer

  2021cites this paper
• LINC01559 accelerates pancreatic cancer cell proliferation and migration through YAP‐mediated pathway

  2020cites this paper
• Immunotherapeutic strategies in pancreatic ductal adenocarcinoma (PDAC): current perspectives and future prospects

  2020cites this paper
• Pancreatic Adenocarcinoma: Unconventional Approaches for an Unconventional Disease

  2020cites this paper
• Regorafenib in patients with refractory metastatic pancreatic cancer: a Phase II study (RESOUND).

  2019cites this paper
• Clinical Trials Targeting the Stroma in Pancreatic Cancer: A Systematic Review and Meta-Analysis

  2019cites this paper
• Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology

  2019cites this paper
• Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches

  2019cites this paper
• N-arylpiperazine-containing compound (C2): An enhancer of sunitinib in the treatment of pancreatic cancer, involving D1DR activation.

  2019cites this paper
• Special Section on Drug Delivery Technologies — Minireview Combination Therapies and Drug Delivery Platforms in Combating Pancreatic Cancer

  2019cites this paper
• VEGFR Inhibitors as Sensitizing Agents for Cancer Chemotherapy

  2019cites this paper
• Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: does sequence matter?

  2019cites this paper
• Efficacy and safety of gemcitabine plus anti-angiogenesis therapy for advanced pancreatic cancer: a systematic review and meta-analysis of clinical randomized phase III trials

  2019cites this paper
• Combination Therapies and Drug Delivery Platforms in Combating Pancreatic Cancer

  2019cites this paper
• Network Meta-Analysis of Efficacy and Safety of Chemotherapy and Target Therapy in the First-Line Setting of Advanced Pancreatic Cancer

  2019cites this paper
• The Long Noncoding RNA HOST2 Promotes Gemcitabine Resistance in Human Pancreatic Cancer Cells

  2018cites this paper
• Chemotherapy and radiotherapy for advanced pancreatic cancer.

  2018cites this paper
• Chemotherapy in Pancreatic Cancer: A Systematic Review

  2018cites this paper
• Role of angiogenesis in pancreatic cancer biology and therapy.

  2018cites this paper
• Novel agents for pancreatic ductal adenocarcinoma: emerging therapeutics and future directions

  2018cites this paper
• First-line chemotherapy regimens for locally advanced and metastatic pancreatic adenocarcinoma: a Bayesian analysis

  2018cites this paper
• A Two-Front War : Targeting Synchronous Metastatic Pancreatic and Renal Cell Carcinomas with the Combination of Gemcitabine and Sunitinib

  2017cites this paper
• Chapter 9 – Sunitinib

  2017cites this paper
• Antitumor activity of gemcitabine against high-grade meningioma in vitro and in vivo

  2017cites this paper
• miRNA: A Diagnostic and Therapeutic Tool for Pancreatic Cancer.

  2017cites this paper
• Antitumor activity of gemcitabine against high-grade meningioma in vitro and in vivo.

  2017cites this paper
• Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro‐intestinal cancers Part 1: GI carcinomas

  2017cites this paper
• The long non-coding RNA HOTAIR enhances pancreatic cancer resistance to TNF-related apoptosis-inducing ligand

  2017cites this paper
• Randomized Clinical Trials in Pancreatic Cancer.

  2017cites this paper
• Gemcitabine Conjugated Chitosan and Double Antibodies (Abc-GC-Gemcitabine Nanoparticles) Enhanced Cytoplasmic Uptake of Gemcitabine and Inhibit Proliferation and Metastasis In Human SW1990 Pancreatic Cancer Cells

  2017cites this paper
• Current advances of long non-coding RNA highly upregulated in liver cancer in human tumors

  2017cites this paper
• Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts

  2017cites this paper
• Pancreatic Cancer: Promises and Failures of Target Therapies.

  2016cites this paper
• Treatment of gastric outlet obstruction that results from unresectable gastric cancer: Current evidence.

  2016cites this paper
• Current therapeutic strategies for advanced pancreatic cancer: A review for clinicians.

  2016cites this paper
• Angiogenesis in pancreatic ductal adenocarcinoma: A controversial issue

  2016cites this paper
• Systematic review and meta-analysis on targeted therapy in advanced pancreatic cancer.

  2016cites this paper
• The pancreatic niche inhibits the effectiveness of sunitinib treatment of pancreatic cancer

  2016cites this paper
• LncRNAs in pancreatic cancer

  2016cites this paper
• Progression-free survival as a surrogate for overall survival in first-line chemotherapy for advanced pancreatic cancer.

  2016cites this paper
• Novel agents for advanced pancreatic cancer

  2015cites this paper
• Gemcitabine and S-1 combination chemotherapy versus gemcitabine alone for locally advanced and metastatic pancreatic cancer: a meta-analysis of randomized controlled trials in Asia

  2015cites this paper
• Chapter 44 - Cytostatic Agents

  2015cites this paper
• Impact of Comorbidity and Age on Determinants Therapeutic Strategies in Advanced Pancreatic Head Cancer Patients With Obstructive Jaundices

  2015cites this paper
• A case of metastatic renal cell carcinoma and bile duct carcinoma treated with a combination of sunitinib and gemcitabine

  2015cites this paper
• Clinical response to sunitinib as a multitargeted tyrosine-kinase inhibitor (TKI) in solid cancers: a review of clinical trials

  2014cites this paper
• The Dual PI3K/mTOR Inhibitor NVP-BEZ235 Enhances the Antitumoral Activity of Gemcitabine in Human Pancreatic Cancer Cell Lines

  2014cites this paper